Company news
Recce Pharmaceuticals Ltd. news in 2020
Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2020, newest first.
Positive Intranasal Animal Data against SARS-CoV-2 in Study
December 22, 2020
RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
December 7, 2020
Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
November 25, 2020
Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
November 22, 2020
Encouraging Results Against SARS-CoV-2 Virus
November 10, 2020
HREC Approval to Start Phase I/II Burns Wound Study
October 15, 2020
Murdoch Childrens Research Institute, R435 Against H.Pylori
September 30, 2020
Recce Completes Capital Raising of $27.95m
September 23, 2020
R327 Phase I Study - Australias CMAX Clinical Facility
September 10, 2020
Positive & Concentration-Dependent Efficacy Against COVID-19
September 8, 2020
Recce Pharmaceuticals Receives Innovation Connections Grant
August 31, 2020
Recce Pharmaceuticals Appoints James Graham as CEO
August 28, 2020
Positive Oral Data on New RECCE 435 Against H. pylori
August 4, 2020
US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
July 16, 2020
RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
July 8, 2020
Response to ASX Price and Volume Query
May 27, 2020
Positive Data on RECCE 327 Against Neisseria gonorrhoeae
May 4, 2020
Further Positive Data on RECCE 327 Against MRSA Superbug
April 23, 2020
Positive Data on RECCE 327 Against Influenza A
April 20, 2020
Recce Signs Phase I Human Clinical Trial Agreement
April 8, 2020
First-in-Human Clinical Trial Progress Update
March 16, 2020
Half Yearly Report and Accounts
February 27, 2020
Positive Efficacy Data in Kidney/UTI infections animal model
February 13, 2020
Positive Data from RECCE 327 Antibiotic Safety Studies
February 9, 2020
Appendix 4C and Commentary
January 31, 2020